

Xunfei Healthcare (2506 HK)

Leading the healthcare AI revolution; Initiate with BUY

Xunfei Healthcare leads China's healthcare AI market, with a 5.9% market share in 2023, according to F&S. Leveraging its Spark Medical Model, Xunfei Healthcare has developed various products and solutions to improve the operational efficiency and capabilities of primary healthcare (PHC) providers, hospitals (B), patients (C), and regional administrators (G). Driven by favorable policies and growing demand for smart transformation in healthcare institutions, the Company's revenue increased rapidly, with a 2021-2023 CAGR of 22.2%. We expect Xunfei Healthcare's revenue to increase at a CAGR of 36.9% from 2023 to 2026. We initiate coverage at BUY and derive a TP of HK\$170.56, based on a 13x 2026E P/S.

- **Supportive policies accelerate healthcare AI application.** Healthcare institutions in China are undergoing an intelligent transformation, with AI increasingly integrated into consultation, medical record management, and insurance risk control. Multiple national policies continued to promote AI applications to enhance medical services. According to F&S, China's healthcare AI market is expected to expand from RMB8.8bn in 2023 to RMB315.7bn in 2033E, representing a CAGR of 43.1%.
- **Technological backing from iFlytek and deepening B2B partnerships help strengthen Xunfei Healthcare's leadership.** Leveraging the leading foundational model capabilities of iFlytek and extensive clinical experience and data accumulated from daily operation of its AI solutions, Xunfei Healthcare continuously upgrades the Spark Medical Model. In Mar 2025, the Company launched the Spark Medical Model X1, which outperformed GPT-4o and DeepSeek R1 in key medical reasoning tasks, demonstrating superior clinical support. The Company also continuously strengthens its B2B partnerships to build a robust ecosystem and solidify its commercial channel barriers.
- **Expanding customer base drove revenue growth: robust B2B and B2C growth and steady G-end.** As of Dec 9, 2024, the Company had provided products and services to approximately 60,000 PHCs across over 610 counties in more than 30 provinces, and had entered over 500 graded hospitals. Accelerating intelligent transformation in hospitals drove strong growth in the Company's hospital services, post-discharge management, and cloud medical imaging businesses. The aging population drove strong growth of hearing aids. Therefore, Xunfei Healthcare's B2B and B2C revenue contribution grew rapidly and we believe this trend is likely to continue. In 1H24, the hospital and patient service revenue surged 146% YoY in 1H24, representing 66.9% (+29 ppts YoY) of total revenue.
- **Initiate at BUY with TP of HK\$170.65.** We are bullish on healthcare AI's prospects. We expect the Company to increase its revenue at a CAGR of 36.9% from 2023 to 2026 and rapidly narrow its net losses. We derive our TP of HK\$170.56, based on a 13x 2026E P/S, to reflect the Company's high-growth potential.

Earnings Summary

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E
Revenue (RMB mn)	472	556	725	1,020	1,427
YoY growth (%)	26.7	17.9	30.4	40.7	39.9
Attributable net profit (RMB mn)	(189)	(145)	(185)	(106)	(43)
Adjusted net profit (RMB mn)	(111)	(57)	(24)	(13)	50
EPS (Adjusted) (RMB cents)	(99.56)	(51.29)	(19.44)	(10.39)	41.47
P/S (x)	31.3	26.6	20.4	14.5	10.3
Net gearing (%)	(41.7)	(10.6)	(44.5)	(26.5)	(6.5)

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Initiate)

Target Price HK\$170.56
Up/Downside 30.0%
Current Price HK\$131.20

China Healthcare

Jill WU, CFA
 (852) 3900 0842
 jillwu@cmbi.com.hk

Cathy WANG
 (852) 3916 1729
 cathywang@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	15,859.2
Avg 3 mths t/o (HK\$ mn)	21.3
52w High/Low (HK\$)	NA/NA
Total Issued Shares (mn)	120.9

Source: FactSet

Shareholding Structure

iFlytek Co., Ltd.	49.4%
Hefei Zhengsheng Information Technology	16.1%


Source: HKEx

Share Performance

	Absolute	Relative
1-mth	-9.3%	-10.1%
3-mth	NM	NM
6-mth	NM	NM

Source: FactSet

12-mth Price Performance



Source: FactSet

We expect B2B (hospital services) and B2C (patient services) segments to continue driving Xunfei Healthcare's revenue growth. We expect Xunfei Healthcare's revenue to increase at a CAGR of 36.9% from 2023 to 2026E.

Xunfei Healthcare's PHC services and regional healthcare solutions businesses (G-end) were under pressure in 2024, due to macroeconomic factors and local government fiscal constraints. However, we expect a recovery and steady growth in these two business segments from 2025 onward, driven by national policies aimed at alleviating local government debt and continued strong support for primary healthcare institutions. We expect revenue of PHC services to change by -3.8%/ 15.0%/ 10.0% YoY to RMB231mn/ 265mn/ 292mn in 2024E/ 2025E/ 2026E, respectively. We forecast revenue of regional healthcare solutions to change by -5.6%/ 15.0%/ 10.0% YoY to RMB110mn/ 127mn/ 139mn in 2024E/ 2025E/ 2026E.

We expect Xunfei Healthcare to benefit significantly from the ongoing wave of hospital intelligent transformation. Hospital services (B-end) are expected to experience rapid growth, with revenue increasing by 104.7%/ 70.0%/ 65.0% YoY to RMB133mn/ 226mn/ 373mn in 2024E/ 2025E/ 2026E, respectively.

We expect the Company's patient services segment to grow rapidly, driven by increased sales of medical equipment such as hearing aids, as well as strong growth in imaging cloud and post-discharge management services. We expect revenue for patient services to increase by 86.5%/ 60.0%/ 55.0% YoY to RMB251mn/ 402mn/ 623mn in 2024E/ 2025E/ 2026E, respectively.

Fig 1: Revenue forecasts (2021-2026E) - by segment

RMB mn		2021	2022	2023	2024E	2025E	2026E
PHC Services	YoY	216	298	240	231	265	292
			38.27%	-19.56%	-3.79%	15.00%	10.00%
Hospital Services	YoY	82	43	65	133	226	373
			-47.19%	49.27%	104.68%	70.00%	65.00%
Patient Services	YoY	32	37	135	251	402	623
			14.28%	265.43%	86.47%	60.00%	55.00%
Regional Healthcare Solutions	YoY	42	93	117	110	127	139
			121.09%	24.85%	-5.55%	15.00%	10.00%
Total revenue		372	472	556	725	1,020	1,427
YoY			26.69%	17.86%	30.38%	40.68%	39.92%

Source: Xunfei Healthcare, CMBIGM estimates

Figure 2: Peer comparison

Company	Ticker	Rating	Price	Market Cap	Revenue (US\$m)		YoY (%)		PS (x)	
			(LC)	(US\$m)	2025E	2026E	2025E	2026E	2025E	2026E
Overseas market										
Tempus AI	TEM US	NA	49.9	8,588	1,237	1,556	78%	26%	6.9	5.5
Doximity Inc	DOCS US	NA	62.4	11,714	566	636	19%	12%	20.7	18.4
Veeva Systems Inc	VEEV US	NA	237.0	38,471	2,725	3,050	16%	12%	14.1	12.6
Salesforce	CRM US	NA	280.8	269,801	37,954	40,845	9%	8%	7.1	6.6
Recursion Pharmaceuticals	RXR US	NA	6.8	2,750	87	131	28%	51%	31.7	21.0
Average							30%	22%	16.1	12.8
H & A share market										
Medlive	2192 HK	NA	1,392	14.8	97	122	28%	26%	14.3	11.3
XtalPi	2228 HK	BUY	3,497	6.8	61	106	73%	72%	56.5	32.8
Yidu Tech	2158 HK	NA	946	6.9	109	123	-5%	13%	8.6	7.7
China Reform Health Manage	000503 CH	NA	1,736	12.8	69	85	23%	23%	25.4	20.6
Winning Health	300253 CH	NA	3,597	11.9	546	643	16%	18%	6.7	5.7
B-Soft	300451 CH	NA	1,529	7.1	273	308	13%	13%	5.6	5.0
Average							24%	27%	19.5	13.8
Overall average									18.0	13.4

Source: Bloomberg, CMBIGM estimates, as of Mar 18, 2025

Fig 3: CMBIGM estimates vs consensus

RMB mn	CMBI			Consensus			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	725	1,020	1,427	756	1,083	1,525	-4.1%	-5.8%	-6.4%
Gross profit	414	593	843	435	632	906	-4.8%	-6.2%	-6.9%
Net profit	-185	-106	-43	-104	-64	14	NA	NA	NA
EPS (RMB)	-1.53	-0.88	-0.36	-0.86	-0.53	0.11	NA	NA	NA
Gross margin	57.14%	58.14%	59.08%	57.57%	58.40%	59.40%	-0.43 ppt	-0.26 ppt	-0.32 ppt
Net Margin	-25.47%	-10.38%	-3.03%	-13.78%	-5.95%	0.92%	-11.69 ppt	-4.43 ppt	-3.94 ppt

Source: Company data, Bloomberg, CMBIGM estimates

Investment Risks

- 1) Underperformance in regional expansion and market development;
- 2) Negative impact of macroeconomic or industry headwinds on hospital procurement demand;
- 3) Weaker-than-anticipated demand for healthcare AI solutions;
- 4) Risk of intensified competition in the healthcare AI market.

Financial Summary

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Revenue	372	472	556	725	1,020	1,427
Cost of goods sold	(185)	(241)	(241)	(311)	(427)	(584)
Gross profit	188	231	315	414	593	843
Selling expense	(91)	(160)	(163)	(196)	(255)	(328)
Admin expense	(69)	(109)	(113)	(131)	(168)	(214)
R&D expense	(160)	(242)	(264)	(290)	(357)	(428)
Other income	31	44	49	56	66	81
Other gains/(losses)	(0)	3	1	0	0	0
Interest expense	(3)	(1)	(1)	(3)	(3)	(5)
Others	(7)	(10)	(10)	(68)	0	0
Pre-tax profit	(111)	(244)	(187)	(217)	(125)	(51)
Income tax	22	36	33	33	19	8
After tax profit	(89)	(209)	(154)	(185)	(106)	(43)
Minority interest	(6)	(19)	(9)	0	0	0
Attributable net profit	(84)	(189)	(145)	(185)	(106)	(43)
Adjusted net profit	(48)	(111)	(57)	(24)	(13)	50

BALANCE SHEET	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Current assets	727	652	853	1,280	1,341	1,515
Cash & equivalents	434	163	143	540	372	243
Restricted cash	4	4	6	7	8	9
Account receivables	177	305	533	546	741	997
Inventories	32	47	74	77	103	138
Financial assets at FVTPL	0	85	25	25	25	25
Other current assets	59	31	65	65	65	65
Contract assets	20	16	8	20	28	39
Non-current assets	287	378	384	429	477	544
PP&E	8	10	14	17	20	23
Right-of-use assets	3	1	2	1	1	1
Deferred income tax	43	75	106	106	106	106
Intangibles	205	166	158	151	143	135
Goodwill	24	24	24	24	24	24
Other non-current assets	3	102	81	131	184	256
Total assets	1,014	1,030	1,238	1,709	1,818	2,060
Current liabilities	488	603	671	777	898	1,089
Short-term borrowings	77	0	88	138	138	188
Account payables	187	311	380	426	526	640
Other current liabilities	172	265	163	163	163	163
Lease liabilities	2	1	1	1	1	1
Contract liabilities	50	27	40	50	70	98
Non-current liabilities	29	26	17	17	17	17
Long-term borrowings	8	8	0	0	0	0
Other non-current liabilities	21	18	17	17	17	17
Total liabilities	517	630	688	794	915	1,106
Share capital	37	111	114	121	121	121
Other reserves	390	230	385	743	731	781
Total shareholders equity	497	400	550	915	903	953
Minority interest	70	59	51	51	51	51
Total equity and liabilities	1,014	1,030	1,238	1,709	1,818	2,060

CASH FLOW	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	(111)	(244)	(187)	(217)	(125)	(51)
Depreciation & amortization	37	54	42	41	41	41
Tax paid	4	(0)	0	33	19	8
Change in working capital	(45)	(59)	(292)	(22)	(160)	(233)
Others	63	135	123	116	118	120
Net cash from operations	(53)	(114)	(314)	(50)	(108)	(116)
Investing						
Capital expenditure	(6)	(6)	(11)	(10)	(10)	(10)
Others	(52)	(88)	11	(45)	(47)	(48)
Net cash from investing	(58)	(93)	0	(55)	(57)	(58)
Financing						
Net borrowings	77	(77)	88	50	0	50
Proceeds from share issues	390	10	210	524	0	0
Others	(22)	3	(5)	(71)	(3)	(5)
Net cash from financing	445	(64)	293	503	(3)	45
Net change in cash						
Cash at the beginning of the year	100	434	163	143	540	372
Exchange difference	0	0	0	0	0	0
Cash at the end of the year	434	163	143	540	372	243
GROWTH	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Revenue	na	26.7%	17.9%	30.4%	40.7%	39.9%
Gross profit	na	22.9%	36.4%	31.7%	43.1%	42.2%
PROFITABILITY	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Gross profit margin	50.4%	48.9%	56.6%	57.1%	58.1%	59.1%
Adj. net profit margin	(13.0%)	(23.4%)	(10.2%)	(3.2%)	(1.2%)	3.5%
Return on equity (ROE)	na	(42.2%)	(30.5%)	(25.2%)	(11.6%)	(4.7%)
GEARING/LIQUIDITY/ACTIVITIES	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Net debt to equity (x)	(0.7)	(0.4)	(0.1)	(0.4)	(0.3)	(0.1)
Current ratio (x)	1.5	1.1	1.3	1.6	1.5	1.4
VALUATION	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
P/E	ns	ns	ns	ns	ns	ns
P/B	23.0	33.9	24.7	16.1	16.4	15.5
Div yield (%)	0.0	0.0	0.7	0.0	0.0	0.0

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report. CMBIGM or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.